Prognosis
Singapore Expert Committee Backs Pfizer-BioNTech Vaccine
- City-state has received first batch of vaccine shots
- Medical workers and elderly should get priority, experts say
Photographer: Ronny Hartmann/AFP/Getty Images
This article is for subscribers only.
A group of top Singapore health experts backed the government’s move to approve the Pfizer Inc. and BioNTech SE’s coronavirus vaccine after it conducted an independent review of clinical data on its safety and efficacy.
The vaccine demonstrated a high efficacy rate of 95% and its safety profile is consistent with the high standards set for other registered vaccines used in immunization against other diseases, the committee of experts said in a statement issued by the health ministry on Sunday. It is suitable for use for those aged 16 and above, and is expecting further trial data on other groups, such as pregnant women, the committee said.